Medication info
Subast Tablets 2.5 mg (Rosuvastatin Calcium)

Subast Tablets 2.5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›2.6mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablets
Packaging
PTP - 30 tablets/box [15 tablets/PTP x 2], bottle - 30 tablets/bottle, bottle - 300 tablets/bottle
Approval status
Active

MFDS item code 202105987 · Approved 2021.08.17 · Insurance code 643508450

Summary

Main use
Treatment of primary hypercholesterolemia and mixed hyperlipidemia
Who uses it
Adults
Adult dosage
Patients taking this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 2.5 or 5 milligrams once daily; for patients who require a greater reduction in LDL cholesterol, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 2.5 or5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 2.5 or5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of primary hypercholesterolemia and mixed hyperlipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
View approved original text

This medication is used for the treatment of primary hypercholesterolemia, particularly heterozygous familial hypercholesterolemia (Type IIa) and mixed dyslipidemia (Type IIb). It is used as an adjunct to diet when the condition is not controlled through diet and exercise alone, effectively managing cholesterol levels in the blood. This helps in the prevention of cardiovascular diseases.

Dosage and Administration

Adult dosage

Patients taking this medicine, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 2.5 or 5 milligrams once daily; for patients who require a greater reduction in LDL cholesterol, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 2.5 or5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 2.5 or5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Precautions

This medication should not be used in certain patients. For example, individuals who are allergic to this drug, have severely impaired liver function, or have muscle disorders should not take this medication. Additionally, it should not be used in patients taking certain other medications, in those with very poor kidney function, or in pregnant or breastfeeding women. This medication can cause muscle issues, so patients at high risk for muscle pain or myopathy should exercise particular caution. If muscle pain or weakness symptoms occur while taking this medication, the doctor should be notified immediately, and discontinuation of the medication should be considered if necessary. Regular liver function tests and muscle enzyme tests are recommended, and individuals with excessive alcohol consumption or liver disease should use this medication cautiously. This medication contains lactose, so patients with lactose intolerance should also take caution. Children, the elderly, and patients with hypothyroidism should consult a doctor before use. Additionally, this medication may interact with other drugs, so if there are any other medications being taken, they must be disclosed. Women who may become pregnant should use appropriate contraception, and it should not be used during pregnancy. Rarely, this medication can cause severe side effects such as liver damage, serious skin reactions, and muscle rupture, so any unusual symptoms should be discussed with healthcare professionals immediately. In case of overdose, no specific antidote exists, and treatment should be symptomatic, with monitoring of liver function and muscle enzyme levels. Lastly, while taking this medication, caution should be exercised as dizziness may occur when driving or operating machinery.

Side effects

Dyspepsia, pruritus, immune thrombocytopenic purpura, facial edema, herpes zoster, vulvar pruritus, itching, rash, urticaria, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, eczema-like drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, increased CK, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. Maintaining a storage temperature of 1 to 30 degrees Celsius is important to preserve the medication's efficacy and safety.

Appearance and packaging

Appearance

White round film-coated tablets

Package unit

PTP - 30 tablets/box [15 tablets/PTP x 2], bottle - 30 tablets/bottle, bottle - 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.